doc.ai and the Stanford University School of Medicine are currently seeking participants for a research study to evaluate if machine intelligence can help predict the optimal anti-epileptic drug. This is a 3 months study, participants are financially compensated, it is all done remotely via the participants’ smartphones via the doc.ai app.
10 – 20 minutes a day
$125 in Amazon Gift Cards
Smartphone-based at-home trial for U.S. residents.
Once enrolled via the doc.ai app, for three months, participants will:
Following the completion of the trial, participants will receive financial compensation.
Read more below or fill in the form to express your interest
Epilepsy, a neurological disorder characterized by unprovoked and recurrent seizures, affects 65 million people across the globe and 3.4 million in the U.S.
Two-thirds of people with epilepsy will gain good control of their symptoms with medications, but a third will not. While the cause of seizures is largely unknown, more than 25 medications have been developed to help manage symptoms. The process of drug selection is still largely a matter of trial and error. There are over 14,000 possible combinations of up to three drugs. Discovering which drugs are effective and which aren’t is a puzzle for clinicians and this is where A.I. may be helpful. Until the right medication combination is established, patients may suffer from severe side effects and adverse reactions, sometimes for years.
“We’re excited to see continued advancement in the way we treat epilepsy,” said Sonya Dumanis, PhD, Senior Director of Innovation, Epilepsy Foundation. “The Digital Health Trial is another research milestone for our community as it has the potential to provide physicians and people with epilepsy with new options to optimize and personalize treatment. Our hope is that the use of A.I. to develop a predictive model to help identify the right approach for each person will help those struggling to gain better seizure control.”
“doc.ai has a robust multi-omics data pipeline, and we’re proud to contribute DNA tests free of charge to advance medicine,” said Troy Moore, Chief Scientific Officer, Kailos Genetics, Inc. “We hope to see some indications of clinical utility for DNA testing and treating someone with a variety of types of epilepsy. It’s early days, and together we’re testing a model of focused delivery to different population groups, which could strengthen links between epilepsy and genetics and show downstream outcomes.”
This study is conducted by Robert Fisher MD, PhD, Maslah Saul Professor and Director of the Stanford Epilepsy Center; Dennis Wall PhD Associate Professor of Pediatrics, Psychiatry and Biomedical Data Sciences at Stanford Medical School and advisor at doc.ai; and Chethan Sarabu MD, Director of Clinical Informatics at doc.ai and physician at Stanford Medicine.
Participation in this study will help advance medication research and contribute to a better understanding of epilepsy. Participants who complete this study will receive a visualization of their symptoms, an individualized report they can share with their doctor, and financial compensation for their time. Questions? Contact us at firstname.lastname@example.org.
If you meet the following requirements, you might be interested in helping advance medication research and contribute to a better understanding of epilepsy.
You have seizures and/or suffer from epilepsy
You take anti-epileptic medication
Must be over the age of 18
Must reside in the U.S. for the duration of the study
Must be able to read, understand and write in English
Must have a smartphone to support the doc.ai app (iOS or Android)
It’s important to note this study is observational, and will not require you to change any of your current medications. Read more below or download the doc.ai app to join the study.